Logo

Tekmira Closes $30M Stock Offering

Oct 24, 2013
Premium

Tekmira Pharmaceuticals this week announced that it has completed the public offering of $30 million of its common stock.

Through the transaction, Tekmira sold 3.75 million shares at $8 apiece. The underwriters of the offering have a 30-day option to purchase an additional 15 percent of the shares to cover over-allotments.

Tekmira stock was selling for around $8.68 during midday trading on Wednesday.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
Tekmira
stock offering
RNAi
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.